The European Patent Office (EPO) has published patent application EP4074833A1, titled "Restricted Immunoglobulin Heavy Chain Mice." The publication date is March 11, 2026, and the applicant is Regeneron Pharmaceuticals, Inc. This patent application falls under the C07K classification, related to peptides and immunoglobulins.

This is a patent publication, not a regulatory rule or guidance that imposes direct compliance obligations on companies. However, it is relevant for pharmaceutical and biotechnology companies operating in the EU, particularly those involved in antibody research and development, as it pertains to intellectual property rights in genetically modified animal models used in drug discovery.